
Arcutis (ARQT) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Mar 2025Income Metrics
Revenue
65.8M
Gross Profit
57.0M
86.59%
Operating Income
-24.5M
-37.25%
Net Income
-25.1M
-38.06%
EPS (Diluted)
$-0.20
Balance Sheet Metrics
Total Assets
344.1M
Total Liabilities
201.4M
Shareholders Equity
142.7M
Debt to Equity
1.41
Cash Flow Metrics
Operating Cash Flow
-25.8M
Free Cash Flow
-31.0M
Revenue & Profitability Trend
Arcutis Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 196.5M | 59.6M | 3.7M | 0 | 0 |
Cost of Goods Sold | 19.1M | 5.0M | 754.0K | 0 | 0 |
Gross Profit | 177.4M | 54.6M | 2.9M | 0 | 0 |
Gross Margin % | 90.3% | 91.6% | 79.5% | 0.0% | 0.0% |
Operating Expenses | |||||
Research & Development | 76.4M | 110.6M | 182.4M | 145.6M | 115.3M |
Selling, General & Administrative | 229.4M | 185.1M | 122.1M | 61.0M | 21.3M |
Other Operating Expenses | - | - | - | - | - |
Total Operating Expenses | 305.8M | 295.7M | 304.6M | 206.5M | 136.6M |
Operating Income | -128.4M | -241.1M | -301.6M | -206.5M | -136.6M |
Operating Margin % | -65.3% | -404.5% | -8,183.0% | 0.0% | 0.0% |
Non-Operating Items | |||||
Interest Income | - | - | - | - | - |
Interest Expense | 27.2M | 29.7M | 15.7M | 0 | 0 |
Other Non-Operating Income | 16.2M | 11.8M | 5.8M | 173.0K | 967.0K |
Pre-tax Income | -139.4M | -259.0M | -311.5M | -206.4M | -135.7M |
Income Tax | 647.0K | 3.1M | 0 | 0 | - |
Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Net Income | -140.0M | -262.1M | -311.5M | -206.4M | -135.7M |
Net Margin % | -71.3% | -439.8% | -8,449.8% | 0.0% | 0.0% |
Key Metrics | |||||
EBITDA | -109.6M | -227.8M | -294.9M | -205.9M | -135.6M |
EPS (Basic) | $-1.16 | $-3.78 | $-5.66 | $-4.18 | $-3.80 |
EPS (Diluted) | $-1.16 | $-3.78 | $-5.66 | $-4.18 | $-3.80 |
Basic Shares Outstanding | 120957633 | 69305487 | 55032265 | 49405575 | 35668152 |
Diluted Shares Outstanding | 120957633 | 69305487 | 55032265 | 49405575 | 35668152 |
Income Statement Trend
Arcutis Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 71.3M | 88.4M | 53.6M | 96.4M | 65.1M |
Short-term Investments | 156.6M | 183.5M | 355.9M | 290.6M | 219.4M |
Accounts Receivable | 73.1M | 25.8M | 8.5M | 0 | - |
Inventory | 14.5M | 13.1M | 7.5M | 0 | - |
Other Current Assets | 8.2M | 8.2M | 6.3M | 8.0M | - |
Total Current Assets | 335.8M | 330.4M | 437.4M | 402.8M | 292.8M |
Non-Current Assets | |||||
Property, Plant & Equipment | 2.0M | 2.4M | 2.7M | 3.0M | 3.3M |
Goodwill | 9.5M | 6.4M | 7.2M | 0 | - |
Intangible Assets | - | - | - | - | - |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 596.0K | 596.0K | 78.0K | 78.0K | 78.0K |
Total Non-Current Assets | 13.1M | 10.9M | 11.9M | 5.4M | 5.4M |
Total Assets | 348.9M | 341.4M | 449.3M | 408.2M | 298.3M |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 14.2M | 12.0M | 8.8M | 7.4M | 7.1M |
Short-term Debt | 820.0K | 735.0K | 657.0K | 433.0K | - |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | - | - | - | - | - |
Total Current Liabilities | 81.0M | 46.7M | 37.8M | 33.3M | 22.6M |
Non-Current Liabilities | |||||
Long-term Debt | 109.8M | 205.2M | 201.9M | 77.1M | 5.0M |
Deferred Tax Liabilities | - | - | - | - | - |
Other Non-Current Liabilities | 570.0K | 849.0K | - | 25.0K | 82.0K |
Total Non-Current Liabilities | 110.3M | 206.0M | 201.9M | 77.1M | 5.0M |
Total Liabilities | 191.3M | 252.7M | 239.7M | 110.5M | 27.6M |
Equity | |||||
Common Stock | 12.0K | 9.0K | 6.0K | 5.0K | 4.0K |
Retained Earnings | -1.1B | -981.9M | -719.8M | -408.3M | -202.0M |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 157.5M | 88.7M | 209.6M | 297.7M | 270.6M |
Key Metrics | |||||
Total Debt | 110.6M | 205.9M | 202.5M | 77.6M | 5.0M |
Working Capital | 254.8M | 283.8M | 399.6M | 369.4M | 270.2M |
Balance Sheet Composition
Arcutis Cash Flow Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | -140.0M | -262.1M | -311.5M | -206.4M | -135.7M |
Depreciation & Amortization | 2.6M | 1.5M | 934.0K | 454.0K | 122.0K |
Stock-Based Compensation | 41.7M | 38.8M | 32.7M | 23.9M | 7.9M |
Working Capital Changes | -46.2M | -20.5M | -14.8M | 488.0K | 5.7M |
Operating Cash Flow | -136.1M | -237.9M | -260.1M | -181.2M | -121.6M |
Investing Activities | |||||
Capital Expenditures | -143.0K | -428.0K | -333.0K | -995.0K | -321.0K |
Acquisitions | - | - | - | - | - |
Investment Purchases | -254.8M | -225.8M | -415.4M | -292.5M | -279.1M |
Investment Sales | 288.8M | 406.5M | 351.5M | 217.6M | 97.6M |
Investing Cash Flow | 33.8M | 180.2M | -64.2M | -76.0M | -181.8M |
Financing Activities | |||||
Share Repurchases | - | - | - | - | - |
Dividends Paid | - | - | - | - | - |
Debt Issuance | 0 | 0 | 125.0M | 74.0M | 0 |
Debt Repayment | -100.0M | - | - | - | - |
Financing Cash Flow | 61.7M | 98.9M | 298.9M | 279.8M | 297.0M |
Free Cash Flow | -117.3M | -247.5M | -281.0M | -175.6M | -113.4M |
Net Change in Cash | -40.6M | 41.2M | -25.5M | 22.7M | -6.4M |
Cash Flow Trend
Arcutis Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-13.78
Forward P/E
-16.31
Price to Book
13.78
Price to Sales
7.27
PEG Ratio
0.20
Profitability Ratios
Profit Margin
-35.40%
Operating Margin
-17.93%
Return on Equity
-57.33%
Return on Assets
-13.46%
Financial Health
Current Ratio
3.20
Debt to Equity
79.27
Beta
1.84
Per Share Data
EPS (TTM)
$-0.73
Book Value per Share
$1.16
Revenue per Share
$2.10
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
arqt | 1.9B | -13.78 | 13.78 | -57.33% | -35.40% | 79.27 |
Vertex | 101.3B | 28.08 | 5.90 | 22.77% | 31.86% | 8.89 |
Regeneron | 63.6B | 15.12 | 2.09 | 15.34% | 31.37% | 9.04 |
Sarepta Therapeutics | 2.0B | 19.98 | 1.46 | -4.76% | -2.34% | 100.51 |
Adaptive | 1.9B | -12.04 | 10.69 | -57.60% | -59.07% | 121.39 |
ProKidney | 1.8B | -3.89 | 0.93 | -40.52% | 0.00% | 1.30 |
Financial data is updated regularly. All figures are in the company's reporting currency.